Clinical and Molecular Outcomes of Dabrafenib/Trametinib-Based Combination Therapy in Acquired BRAF V600E-Mutant NSCLC Following Tyrosine Kinase Inhibitor Resistance: A Preliminary Single-Center Retrospective Study.
Dabrafenib/trametinib-based combination therapy may show clinical activity in selected patients with acquired BRAF V600E-mutant NSCLC after TKI resistance, however, the extremely small sample size, heterogeneous outcomes, and clinically significant toxicities preclude definitive conclusions regarding efficacy or safety...